358 related articles for article (PubMed ID: 1740679)
21. The addition of daunorubicin to imatinib mesylate in combination with cytarabine improves the response rate and the survival of patients with myeloid blast crisis chronic myelogenous leukemia (AFR01 study).
Deau B; Nicolini FE; Guilhot J; Huguet F; Guerci A; Legros L; Pautas C; Berthou C; Guyotat D; Cony-Makhoul P; Gardembas M; Michallet M; Hayette S; Cayuela JM; Weiss IR; Réa D; Castaigne S; Mahon FX; Guilhot F; Rousselot P
Leuk Res; 2011 Jun; 35(6):777-82. PubMed ID: 21145590
[TBL] [Abstract][Full Text] [Related]
22. Simultaneous administration of granulocyte-macrophage colony-stimulating factor and cytosine arabinoside for the treatment of relapsed acute myeloid leukemia.
Cannistra SA; DiCarlo J; Groshek P; Kanakura Y; Berg D; Mayer RJ; Griffin JD
Leukemia; 1991 Mar; 5(3):230-8. PubMed ID: 1826536
[TBL] [Abstract][Full Text] [Related]
23. High-dose cytosine arabinoside and idarubicin treatment of chronic myeloid leukemia in myeloid blast crisis.
Barone S; Baer MR; Sait SN; Lawrence D; Block AW; Wetzler M
Am J Hematol; 2001 Jun; 67(2):119-24. PubMed ID: 11343384
[TBL] [Abstract][Full Text] [Related]
24. Homoharringtonine combined with cytarabine to treat chronic myelogenous leukemia in myeloid blast crisis and its impact on bone marrow CD34+CD7+ cells.
Li Y; Deng Z; Zho J; Ding B; Shi Y; Li Y
Acta Haematol; 2014; 132(2):172-6. PubMed ID: 24603361
[TBL] [Abstract][Full Text] [Related]
25. A phase I-II trial of escalating doses of mitoxantrone with fixed doses of cytarabine plus fludarabine as salvage therapy for patients with acute leukemia and the blastic phase of chronic myelogenous leukemia.
Koller CA; Kantarjian HM; Feldman EJ; O'Brien S; Rios MB; Estey E; Keating M
Cancer; 1999 Dec; 86(11):2246-51. PubMed ID: 10590364
[TBL] [Abstract][Full Text] [Related]
26. Results of decitabine therapy in the accelerated and blastic phases of chronic myelogenous leukemia.
Kantarjian HM; O'Brien SM; Keating M; Beran M; Estey E; Giralt S; Kornblau S; Rios MB; de Vos D; Talpaz M
Leukemia; 1997 Oct; 11(10):1617-20. PubMed ID: 9324279
[TBL] [Abstract][Full Text] [Related]
27. Granulocyte-macrophage colony-stimulating factor in association to timed-sequential chemotherapy with mitoxantrone, etoposide, and cytarabine for refractory acute myelogenous leukemia.
Archimbaud E; Fenaux P; Reiffers J; Cordonnier C; Leblond V; Travade P; Troussard X; Tilly H; Auzanneau G; Marie JP
Leukemia; 1993 Mar; 7(3):372-7. PubMed ID: 8445942
[TBL] [Abstract][Full Text] [Related]
28. Results of decitabine (5-aza-2'deoxycytidine) therapy in 130 patients with chronic myelogenous leukemia.
Kantarjian HM; O'Brien S; Cortes J; Giles FJ; Faderl S; Issa JP; Garcia-Manero G; Rios MB; Shan J; Andreeff M; Keating M; Talpaz M
Cancer; 2003 Aug; 98(3):522-8. PubMed ID: 12879469
[TBL] [Abstract][Full Text] [Related]
29. A dose intensive regimen of cytosine arabinoside and daunorubicin for chronic myelogenous leukemia in blast crisis.
Kouides PA; Rowe JM
Leuk Res; 1995 Oct; 19(10):763-70. PubMed ID: 7500655
[TBL] [Abstract][Full Text] [Related]
30. Treatment of chronic myeloid leukemia in the blastic phase with fludarabine, cytosine arabinoside and G-CSF (FLAG).
Tedeschi A; Montillo M; Ferrara F; Nosari A; Mele G; Copia C; Leoni P; Morra E
Eur J Haematol; 2000 Mar; 64(3):182-7. PubMed ID: 10997884
[TBL] [Abstract][Full Text] [Related]
31. High-dose cytarabine, idarubicin, and granulocyte colony-stimulating factor remission induction therapy for previously untreated de novo and secondary adult acute myeloid leukemia.
Baer MR; Christiansen NP; Frankel SR; Brunetto VL; Mrózek K; Bloomfield CD; Herzig GP
Semin Oncol; 1993 Dec; 20(6 Suppl 8):6-12. PubMed ID: 7507264
[TBL] [Abstract][Full Text] [Related]
32. Topotecan-based combination chemotherapy in patients with transformed chronic myelogenous leukemia and advanced myelodysplastic syndrome.
Park SJ; Kim DW; Kim HJ; Eom HS; Min CK; Lee JW; Min WS; Kim CC
Korean J Intern Med; 2000 Jul; 15(2):122-6. PubMed ID: 10992724
[TBL] [Abstract][Full Text] [Related]
33. Treatment of terminal-phase chronic myelogenous leukemia with intermediate-dose cytarabine and hydroxyurea.
Lazzarino M; Morra E; Brusamolino E; Alessandrino EP; Orlandi E; Pagnucco G; Castagnola C; Bernasconi P; Merante S; Bonfichi M
Hematol Oncol; 1991; 9(6):299-305. PubMed ID: 1748396
[TBL] [Abstract][Full Text] [Related]
34. Treatment of blastic phase chronic myeloid leukemia with mitoxantrone, cytosine arabinoside and high dose methylprednisolone.
Bolaman Z; Köseoğlu M; Ayyildiz O; Kadiköylü G; Sönmez HM; Demir S; Müftüoğlu E
Haematologia (Budap); 2002; 32(1):49-57. PubMed ID: 12243555
[TBL] [Abstract][Full Text] [Related]
35. Idarubicin/cytosine arabinoside and mitoxantrone/etoposide for the treatment of de novo acute myelogenous leukemia.
Haas R; Ho AD; Del Valle F; Fischer JT; Ehrhardt R; Döhner H; Witt B; Huberts H; Kaplan E; Hunstein W
Semin Oncol; 1993 Dec; 20(6 Suppl 8):20-6. PubMed ID: 8290968
[TBL] [Abstract][Full Text] [Related]
36. Etoposide, intermediate-dose cytarabine and carboplatin (VAC): a combination therapy for the blastic phase of chronic myelogenous leukemia.
Montefusco E; Petti MC; Alimena G; Latagliata R; Celesti F; Capria S; Amadori S; Avvisati G; Mandelli F
Ann Oncol; 1997 Feb; 8(2):175-9. PubMed ID: 9093727
[TBL] [Abstract][Full Text] [Related]
37. Phase I clinical and laboratory evaluation of topotecan and cytarabine in patients with acute leukemia.
Seiter K; Feldman EJ; Halicka HD; Traganos F; Darzynkiewicz Z; Lake D; Ahmed T
J Clin Oncol; 1997 Jan; 15(1):44-51. PubMed ID: 8996123
[TBL] [Abstract][Full Text] [Related]
38. Phase II study of mitoxantrone and 5-azacytidine for accelerated and blast crisis of chronic myelogenous leukemia: a study of the Eastern Cooperative Oncology Group.
Dutcher JP; Eudey L; Wiernik PH; Paietta E; Bennett JM; Arlin Z; Kellermeyer R; Rowe J; O'Connell M; Oken M
Leukemia; 1992 Aug; 6(8):770-5. PubMed ID: 1379312
[TBL] [Abstract][Full Text] [Related]
39. Granulocyte colony-stimulating factor following chemotherapy in elderly patients with newly diagnosed acute myelogenous leukemia.
Maslak PG; Weiss MA; Berman E; Yao TJ; Tyson D; Golde DW; Scheinberg DA
Leukemia; 1996 Jan; 10(1):32-9. PubMed ID: 8558934
[TBL] [Abstract][Full Text] [Related]
40. [Efficacy of imatinib mesylate, a specific inhibitor of BCR/ABL tyrosine kinase, on chronic myeloid leukemia in blast phase].
Zhang GC; Zheng D; Li QH; Li XH; Cai CC; Luo SK; Li J; Peng AH; Tong XZ; Tan EX; Hong WD
Ai Zheng; 2004 Dec; 23(12):1696-9. PubMed ID: 15601563
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
